{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:08:18Z","timestamp":1779376098598,"version":"3.53.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.revmed.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:24:25Z","timestamp":1762345465000},"page":"147-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticorps anti-rituximab dans les maladies auto-immunes et les h\u00e9mopathies malignes\u00a0: mise au point"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3601-0572","authenticated-orcid":false,"given":"Maxime","family":"Teisseyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3543","authenticated-orcid":false,"given":"Marco","family":"Allinovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levraut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Lomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5837-9469","authenticated-orcid":false,"given":"Marion","family":"Cremoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.revmed.2025.09.006_bib0005","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2025.09.006_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.2000.1693","article-title":"Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines","volume":"204","author":"Flieger","year":"2000","journal-title":"Cell Immunol"},{"issue":"12","key":"10.1016\/j.revmed.2025.09.006_bib0015","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1073\/pnas.1131899100","article-title":"Crystalline monoclonal antibodies for subcutaneous delivery","volume":"100","author":"Yang","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.revmed.2025.09.006_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.revmed.2025.09.006_bib0025","doi-asserted-by":"crossref","first-page":"738788","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2025.09.006_bib0030","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ekir.2023.10.023","article-title":"Optimization of rituximab therapy in adult patients with PLA2R1-associated membranous nephropathy with artificial intelligence","volume":"9","author":"Destere","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.revmed.2025.09.006_bib0035","doi-asserted-by":"crossref","first-page":"sfaf113","DOI":"10.1093\/ckj\/sfaf113","article-title":"Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor-associated membranous nephropathy","volume":"18","author":"Teisseyre","year":"2025","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.revmed.2025.09.006_bib0040","doi-asserted-by":"crossref","first-page":"e093920","DOI":"10.1136\/bmjopen-2024-093920","article-title":"Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial","volume":"15","author":"Teisseyre","year":"2025","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.revmed.2025.09.006_bib0045","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1634\/theoncologist.2016-0061","article-title":"Antidrug antibody formation in oncology: clinical relevance and challenges","volume":"21","author":"van Brummelen","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.revmed.2025.09.006_bib0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"BioDrugs"},{"issue":"3\u20134","key":"10.1016\/j.revmed.2025.09.006_bib0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4103\/ijmr.IJMR_312_19","article-title":"Development of anti-rituximab antibodies in rituximab-treated patients: related parameters & consequences","volume":"155","author":"Saffari","year":"2022","journal-title":"Indian J Med Res"},{"issue":"8","key":"10.1016\/j.revmed.2025.09.006_bib0060","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.revmed.2025.09.006_bib0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40259-019-00398-7","article-title":"A randomized, double-blind, efficacy and safety Study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera\u00ae) in subjects with previously untreated CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL)","volume":"34","author":"Sharman","year":"2020","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.revmed.2025.09.006_bib0070","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.imbio.2016.11.011","article-title":"Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology","volume":"222","author":"Sent\u00eds","year":"2017","journal-title":"Immunobiology"},{"issue":"12","key":"10.1016\/j.revmed.2025.09.006_bib0075","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/j.1600-6143.2008.02411.x","article-title":"A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation","volume":"8","author":"Zarkhin","year":"2008","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.revmed.2025.09.006_bib0080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/acr.23771","article-title":"Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference rituximab in patients with active rheumatoid arthritis","volume":"71","author":"Tony","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"25","key":"10.1016\/j.revmed.2025.09.006_bib0085","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.revmed.2025.09.006_bib0090","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.revmed.2025.09.006_bib0095","doi-asserted-by":"crossref","first-page":"e1003348","DOI":"10.1371\/journal.pmed.1003348","article-title":"Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: a prospective multicohort study of the ABIRISK consortium","volume":"17","author":"H\u00e4ssler","year":"2020","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.revmed.2025.09.006_bib0100","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/annrheumdis-2019-215200","article-title":"Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus","volume":"78","author":"Wincup","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.revmed.2025.09.006_bib0105","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/rheumatology\/keac608","article-title":"Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus","volume":"62","author":"Wincup","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.revmed.2025.09.006_bib0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-021-02589-6","article-title":"First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis","volume":"23","author":"Faustini","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.revmed.2025.09.006_bib0115","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.revmed.2025.09.006_bib0120","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.revmed.2025.09.006_bib0125","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.revmed.2025.09.006_bib0130","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.revmed.2025.09.006_bib0135","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2025.09.006_bib0140","doi-asserted-by":"crossref","first-page":"859419","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2025.09.006_bib0145","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2025.09.006_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2025.04.059","article-title":"Anti-rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy","author":"Allinovi","year":"2025","journal-title":"Kidney Int Rep [Internet]"},{"issue":"2","key":"10.1016\/j.revmed.2025.09.006_bib0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00467-021-05069-w","article-title":"Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome","volume":"37","author":"Bertrand","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"9950","key":"10.1016\/j.revmed.2025.09.006_bib0160","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.revmed.2025.09.006_bib0165","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00467-020-04629-w","article-title":"Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome","volume":"35","author":"Fujinaga","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1016\/j.revmed.2025.09.006_bib0170","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.ekir.2022.08.006","article-title":"Circulating anti-rituximab antibodies do not affect response to rituximab in steroid-dependent nephrotic syndrome","volume":"7","author":"Angeletti","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.revmed.2025.09.006_bib0175","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.revmed.2025.09.006_bib0180","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamadermatol.2022.2149","article-title":"Evaluation of clinical relevance and biological effects of antirituximab antibodies in patients with pemphigus","volume":"158","author":"Lemieux","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.revmed.2025.09.006_bib0185","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.revmed.2025.09.006_bib0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"issue":"11","key":"10.1016\/j.revmed.2025.09.006_bib0195","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","article-title":"Immunogenicity of protein therapeutics","volume":"28","author":"De Groot","year":"2007","journal-title":"Trends Immunol"},{"issue":"14","key":"10.1016\/j.revmed.2025.09.006_bib0200","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.revmed.2025.09.006_bib0205","first-page":"6851","article-title":"Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33","volume":"61","author":"Ritter","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.revmed.2025.09.006_bib0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/antib9020022","article-title":"Principles of N-linked glycosylation variations of IgG-based therapeutics: pharmacokinetic and functional considerations","volume":"9","author":"Boune","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"6","key":"10.1016\/j.revmed.2025.09.006_bib0215","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/bit.28066","article-title":"Strategies to control therapeutic antibody glycosylation during bioprocessing: synthesis and separation","volume":"119","author":"Edwards","year":"2022","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.revmed.2025.09.006_bib0220","doi-asserted-by":"crossref","first-page":"119523","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.revmed.2025.09.006_bib0225","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s11095-014-1541-x","article-title":"Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics","volume":"32","author":"Ahmadi","year":"2015","journal-title":"Pharm Res"},{"key":"10.1016\/j.revmed.2025.09.006_bib0230","first-page":"81","article-title":"The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development","volume":"112","author":"Patten","year":"2003","journal-title":"Dev Biol (Basel)"},{"issue":"10","key":"10.1016\/j.revmed.2025.09.006_bib0235","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.xphs.2017.05.030","article-title":"Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins","volume":"106","author":"Hamuro","year":"2017","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.revmed.2025.09.006_bib0240","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.revmed.2025.09.006_bib0245","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.revmed.2025.09.006_bib0250","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.4049\/jimmunol.172.9.5405","article-title":"Cathepsin-dependent apoptosis triggered by supraoptimal activation of T lymphocytes: a possible mechanism of high dose tolerance","volume":"172","author":"Michallet","year":"2004","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2025.09.006_bib0255","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4049\/jimmunol.1000422","article-title":"A novel strategy to reduce the immunogenicity of biological therapies","volume":"185","author":"Somerfield","year":"2010","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2025.09.006_bib0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.revmed.2025.09.006_bib0265","doi-asserted-by":"crossref","first-page":"e0195325","DOI":"10.1371\/journal.pone.0195325","article-title":"Identification of HLA-DRB1 association to adalimumab immunogenicity","volume":"13","author":"Liu","year":"2018","journal-title":"PLoS One"},{"issue":"Supplement_1","key":"10.1016\/j.revmed.2025.09.006_bib0270","doi-asserted-by":"crossref","first-page":"S420","DOI":"10.1093\/ecco-jcc\/jjab076.538","article-title":"P414 Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease","volume":"15","author":"Mahmoud","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"12","key":"10.1016\/j.revmed.2025.09.006_bib0275","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1089\/jir.2012.0139","article-title":"Manifestations of antidrug antibodies response: hypersensitivity and infusion reactions","volume":"34","author":"Vultaggio","year":"2014","journal-title":"J Interferon Cytokine Res"},{"issue":"11","key":"10.1016\/j.revmed.2025.09.006_bib0280","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.revmed.2025.09.006_bib0285","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.revmed.2025.09.006_bib0290","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.revmed.2025.09.006_bib0295","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.revmed.2025.09.006_bib0300","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/rheumatology\/kez430","article-title":"Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy","volume":"59","author":"Combier","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.revmed.2025.09.006_bib0305","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/ene.14498","article-title":"Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies","volume":"27","author":"Casertano","year":"2020","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.revmed.2025.09.006_bib0310","first-page":"332","article-title":"Prediction of immunogenicity for therapeutic proteins: state of the art","volume":"10","author":"De Groot","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"6","key":"10.1016\/j.revmed.2025.09.006_bib0315","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1586\/17512433.2013.835698","article-title":"Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics","volume":"6","author":"De Groot","year":"2013","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325007842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866325007842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:37:43Z","timestamp":1779374263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866325007842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0248866325007842"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2025.09.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticorps anti-rituximab dans les maladies auto-immunes et les h\u00e9mopathies malignes\u00a0: mise au point","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}